SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW

Scilex Holding Co

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$2.57−0.26 (-9.19%)

Close on Oct 19, 2026

Market cap: $17.71M
P/E (TTM): –
Dividend yield: –

Scilex Holding Co income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	30	57	47	38	31	24
Cost of Revenue	11	17	16	11	3.63	2.15
Gross Profit	126	167	31	27	28	21
Research & Development	21	9.64	13	9.05	9.20	9.96
Selling, General & Admin	267	119	120	65	51	43
Operating Income	-346	-83	-105	-51	-36	-35
Interest Expense	11	1.96	1.07	9.60	12	13
Interest & Investment Income	–	–	–	–	0.03	–
Other Non-Operating Income	-28	11	-8.89	27	-53	-12
Asset Impairment Charges	2.50	0	0	0	0	–
Gain (Loss) on Investments	19	0	–	–	–	–
Pretax Income	-374	-73	-114	-23	-88	-48
Income Tax Expense	0.03	0.00	0.01	0.00	0.01	-0.05
Net Income incl. Noncontrolling Interests	–	-73	-114	-23	-88	-48
Minority Interest in Earnings	12	–	–	–	–	–
Net Income	-374	-73	-114	-23	-88	-48
Net Income to Common	-402	-73	-167	-23	-88	-48
EPS (Basic)(per share)	-36.48	-7.24	-44.80	-5.95	-23.45	-12.60
EPS (Diluted)(per share)	-36.48	-8.05	-44.80	-5.95	-23.45	-12.60
Shares Outstanding (Basic, Weighted)(shares)	0.01	0.01	3.72	3.84	3.80	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.01	0.01	3.72	3.84	3.80	0.00
EBITDA	-341	-79	-101	-47	-32	-31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 161.1%
Operating margin: -1136.4%
Net margin: -1469.8%
Return on equity, FY2025: 186.8%

Financial strength

Current ratio: 0.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.1%

Valuation

P/E ratio: –
Price to sales: 0.56
Price to book: –
Dividend yield: –